PURPOSE: To evaluate the long-term efficacy of bevacizumab in the treatment of choroidal neovascularization (CNV) secondary to pathological myopia. METHODS: In this retrospective single-center non-comparative study the medical records of 29 eyes from 29 patients with naïve CNV secondary to high myopia and at least 42 months of follow up were reviewed. All eyes received a loading dose of one intravitreal injection per month for two consecutive months and were retreated on an as-needed basis during the course of follow up. The main outcome measures were post-treatment ETDRS best-corrected visual acuity (BCVA) and visual stabilization over time. Stepwise linear regression analysis was performed to identify prognostic factors for visual acuity gain and final visual acuity outcome at 42 months. RESULTS: At 42 months of follow-up bevacizumab was associated with the maintenance of significant benefits in visual acuity compared to baseline. No adverse ocular or systemic effects from treatment were encountered. No statistically significant correlations were found between BCVA change and any of the quantitative variables. However, when final BCVA was taken as a dependent variable and CNV size and pre-treatment VA were included as predictors, a bivariate model was identified by stepwise regression which gave a 75 % of explained variance. CONCLUSIONS: Bevacizumab treatment was found to be efficacious in the treatment of myopic CNV, resulting in stable gains in visual acuity lasting at least 42 months, without any adverse ocular or general events. Myopic CNV size was identified as a significant prognostic factor.
TRAVERSI, C., Nuti, E., Marigliani, D., CEVENINI, G., BALESTRAZZI, A., MARTONE, G., et al. (2015). Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization. GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 253(4), 511-517.
|Titolo:||Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization|
|Citazione:||TRAVERSI, C., Nuti, E., Marigliani, D., CEVENINI, G., BALESTRAZZI, A., MARTONE, G., et al. (2015). Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization. GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 253(4), 511-517.|
|Appare nelle tipologie:||1.1 Articolo in rivista|